Patent · US Active

Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23

US11332525B2 · kind B2 · utility

1Cited by

0References

14Claims

0Family size

Assignees

Ablynx N.V. · BE
Sanofi · FR

Inventors

Heidi Rommelaere · Wondelgem, BE
Christian Asbrand · Frankfurt am Main, DE
Ann Brigé · Ertvelde, BE
Sigrid Cornelis · Gent, BE
Eric Lorent · Zwijnaarde, BE

Key dates

Filing date	Oct 15, 2021
Grant date	May 17, 2022
Priority date	—
Expiry date	Oct 15, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNFα and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.